Merck Capital Ventures

What Merck Capital Ventures does

Merck & Co., Inc. is a publicly traded research-intensive biopharmaceutical company headquartered in Rahway, New Jersey, USA. The firm operates across seven therapeutic areas: oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology. Its commercialized portfolio includes KEYTRUDA (pembrolizumab, PD-1 cancer immunotherapy), the JANUVIA/JANUMET sitagliptin diabetes franchise, ISENTRESS (HIV integrase inhibitor), DELSTRIGO and IDVYNSO (HIV antiretrovirals), M-M-R II (measles/mumps/rubella vaccine), LAGEVRIO (molnupiravir for COVID-19), and antifungals such as NOXAFIL and CANCIDAS. Distribution runs through a network of 35+ Merck Authorized Distributors (AmerisourceBergen, Cardinal Health, McKesson, Henry Schein, Anda, Medline, VaxServe, and others) and a parallel Vaccine Contracted Distributor program.

Beyond human pharmaceuticals, Merck operates a wholly owned Merck Animal Health subsidiary providing parasiticides (BRAVECTO, EXZOLT), livestock antibiotics, and veterinary vaccines. It also runs an Impact Venture Fund subsidiary dedicated to impact investing and venture philanthropy. Patient support is delivered through the Merck Patient Assistance Program, MerckHelps, and the Merck Access Program, providing free medicines and adult vaccines to eligible uninsured/underinsured patients plus insurance navigation.

The revenue model is wholesale pharmaceutical and vaccine sales to authorized distributors serving downstream healthcare providers, with supplementary direct patient support revenue and animal health product sales. R&D modalities span small molecules, biologics, and emerging platforms in macrocyclic peptides and antibody-drug conjugates. Customer base is horizontal, spanning patients, healthcare providers, authorized wholesalers, and veterinarians. Pricing is not publicly disclosed for prescription pharmaceutical products, and patient assistance programs supplement access for eligible individuals.

Name

Merck Capital Ventures

Legal name

Merck & Co., Inc.

Website

https://merck.com

Company type

Public

Founded year

1891

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merck & Co., Inc. is a publicly traded research-intensive biopharmaceutical company headquartered in Rahway, NJ, that develops and commercializes human medicines, vaccines, and animal health products across oncology, infectious disease, diabetes, HIV, and related therapeutic areas.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (4242), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

akta.pro secondary industries

Vaccine Ordering, Inventory Management & Cold-Chain Logistics (HLAJAHAF), Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)

Keywords

• Prescription pharmaceuticals
• Human vaccines
• Animal health products
• Biopharmaceutical research
• Patient assistance programs

Headquarters

HQ city

Woodcliff Lake

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels3 records

Core offering

Merck & Co., Inc. is a research-intensive biopharmaceutical company that develops, manufactures, and markets prescription human medicines, vaccines, and animal health products. Its portfolio spans oncology (e.g., KEYTRUDA), diabetes (JANUVIA/JANUMET franchise), HIV (ISENTRESS), infectious diseases, vaccines (M-M-R II), and animal health (Merck Animal Health including BRAVECTO). The company supplements product sales with patient assistance programs that provide certain medicines free of charge to eligible individuals and information about insurance coverage.

Product overview

Merck & Co., Inc. operates as a premier research-intensive biopharmaceutical company with a diverse portfolio spanning human pharmaceuticals, vaccines, and animal health products. The company offers blockbuster drugs including KEYTRUDA (cancer immunotherapy), JANUVIA/JANUMET franchise (diabetes), ISENTRESS (HIV treatment), and vaccines like M-M-R II. Patient support is provided through the Merck Access Program and Merck Patient Assistance Program. The company also maintains extensive animal health offerings through the Merck Animal Health division, with products including BRAVECTO parasiticides, antibiotic formulations, and various veterinary vaccines and treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Merck Animal Health: The global animal health business unit of Merck, providing pharmaceuticals, vaccines, and parasiticides for livestock and companion animals
• Merck Access Program
• Merck Patient Assistance Program
• MerckManuals
• Merck for Mothers
• MerckHelps

Products and services

• KEYTRUDA (pembrolizumab) PD-1 immunotherapy indicated for cancer treatment, available as concentrate for solution for infusion, injection, and powder for injection formulations.
• JANUVIA (sitagliptin) DPP-4 inhibitor for type 2 diabetes treatment, available as oral tablets.
• JANUMET (sitagliptin and metformin HCl) Combination diabetes medication combining DPP-4 inhibitor with metformin for glycemic control.
• JANUMET XR (sitagliptin and metformin HCl) Extended-Release Extended-release formulation of sitagliptin and metformin combination for type 2 diabetes.
• ISENTRESS (raltegravir) HIV integrase inhibitor available as film-coated tablets, tablets, oral suspension, and chewable tablets for adult and pediatric use.
• ISENTRESS HD (raltegravir) High-dose formulation of HIV integrase inhibitor for oral administration.
• M-M-R II (measles, mumps, rubella) Vaccine Live virus vaccine for immunization against measles, mumps, and rubella.
• MECTIZAN (ivermectin) Antiparasitic medication for oral treatment of onchocerciasis and other parasitic infections.
• LAGEVRIO (molnupiravir) Antiviral medication for oral treatment of COVID-19.
• BRIDION (sugammadex) Selective relaxant binding agent for reversal of neuromuscular blockade during surgery.
• BELSOMRA (suvorexant) Orexin receptor antagonist for treatment of insomnia.
• NOXAFIL (posaconazole) Antifungal medication available as delayed-release tablets, oral suspension, and IV injection.
• DELSTRIGO (doravirine, lamivudine, tenofovir) Combination antiretroviral tablet for HIV-1 treatment.
• IDVYNSO (doravirine and islatravir) Combination tablet for HIV-1 treatment.
• CANCIDAS (caspofungin) Echinocandin antifungal for intravenous injection treating fungal infections.
• INVANZ (ertapenem) Carbapenem antibiotic for injection treating bacterial infections.
• CUBICIN (daptomycin) Lipopeptide antibiotic for injection treating skin and soft tissue infections.
• INTEGRILIN (eptifibatide) Glycoprotein IIb/IIIa inhibitor for acute coronary syndrome treatment.
• EMEND (fosaprepitant/aprepitant) NK-1 receptor antagonist for prevention of chemotherapy-induced nausea.
• DIFICID (fidaxomicin) Macrolide antibiotic for C. difficile infection treatment.
• NUMELVI (atinvicitinib) JAK inhibitor tablet for inflammatory conditions.
• Merck Patient Assistance Program Program providing certain medicines and adult vaccines free of charge to eligible individuals without insurance or whose insurance does not cover their prescription.
• Merck Access Program Program providing information about insurance coverage and financial assistance options for eligible patients.
• Merck Animal Health Products Extensive portfolio of veterinary pharmaceuticals including ectoparasiticides (BRAVECTO, EXZOLT), antibiotics, vaccines, and growth promotants for livestock and companion animals.
• Merck Clinical Trials Clinical trial finder and information service for patients and healthcare professionals.
• Merck Manuals Medical information source covering thousands of topics in all fields of medicine.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core.

• AmerisourceBergen CorporationcoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distributor serving as a Merck Authorized Distributor for pharmaceutical products across the United States.
• Cardinal HealthcoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distributor serving as a Merck Authorized Distributor for pharmaceutical products across the United States.
• McKesson DrugcoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distributor and parent company of multiple specialty distribution subsidiaries including McKesson Medical-Surgical, McKesson Plasma and Biologics, and McKesson Specialty Distribution Services, serving as Merck Authorized Distributor.
• Henry ScheincoreChannel Partner/ Reseller/ DistributorMajor healthcare products distributor serving as Merck Authorized Distributor and Merck Vaccines Prime Distributor.
• Anda, Inc.coreChannel Partner/ Reseller/ DistributorPharmaceutical distribution company serving as Merck Authorized Distributor with AndaMEDS division serving as Merck Vaccines Prime Distributor.
• Medline Industries, LPcoreChannel Partner/ Reseller/ DistributorHealthcare supplies manufacturer and distributor serving as Merck Authorized Distributor and Merck Vaccines Prime Distributor.
• VaxServe, Inc.coreChannel Partner/ Reseller/ DistributorSpecialized vaccine distributor serving as Merck Vaccines Prime Distributor with contractual agreement for physician distribution.
• Besse Drug / Besse MedicalcoreChannel Partner/ Reseller/ DistributorPharmaceutical wholesale distributor serving as both Merck Authorized Distributor and Merck Vaccines Prime Distributor.
• Medico-Mart, Inc.coreChannel Partner/ Reseller/ DistributorPharmaceutical wholesale distributor serving as Merck Authorized Distributor and Merck Vaccines Prime Distributor.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Sanofi is a broad incumbent — global biopharma with overlapping vaccines (Fluzone), immunology, diabetes, and rare disease franchises, plus a separate consumer health business, competing in similar therapeutic categories but with a wider portfolio scope.
• AbbVie: AbbVie is a broad incumbent — large-cap biopharma with strong immunology (Humira/Skyrizi/Rinvoq), oncology, and neuroscience franchises, facing similar patent-cliff dynamics (Humira biosimilar erosion) and competing for similar payer/prescriber mindshare.
• Eli Lilly: Lilly is a broad incumbent — large-cap biopharma with overlap in diabetes (Merck's JANUVIA franchise competes against Lilly's GLP-1 and insulins), oncology, and immunology, operating across a much broader therapeutic footprint.
• Johnson & Johnson (Innovative Medicine): J&J is a broad incumbent — operates Innovative Medicine (pharma) plus MedTech, with overlapping oncology, immunology, infectious disease, and neuroscience franchises, competing with Merck across multiple therapeutic areas but as part of a much wider portfolio.

Direct peers

• Pfizer: Pfizer is a direct peer — a top-tier global biopharmaceutical company with a similarly diversified human pharma portfolio spanning oncology, vaccines, infectious diseases, and primary care, competing head-to-head with Merck in oncology and vaccines.
• Roche: Roche is a direct peer — global biopharma leader in oncology (Tecentriq competes in the IO space with KEYTRUDA), diagnostics, and infectious disease, with comparable blockbuster biologics and a similar innovator-driven business model.
• AstraZeneca: AstraZeneca is a direct peer — global biopharma with strong oncology (Imfinzi/Imjudo in IO), vaccines, infectious disease, and cardiometabolic franchises that directly compete with Merck's KEYTRUDA, vaccines, and JANUVIA franchises.
• Bristol Myers Squibb: BMS is a direct peer — a major biopharma with overlapping oncology (immuno-oncology with Opdivo competing against KEYTRUDA), hematology, and immunology franchises, and a similar large-molecule and small-molecule portfolio mix.
• Novartis: Novartis is a direct peer — large-cap biopharma with overlapping oncology, immunology, and cardiometabolic franchises, comparable in scale and pipeline breadth to Merck and competing for similar physician and payer relationships.
• GSK: GSK is a direct peer — major vaccines and biopharma player (Shingrix, Cervarix), with overlapping respiratory, HIV-adjacent, and infectious disease franchises and a comparable global vaccine distribution footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights6 records

Customer concentration

• Xtwitter.com/Merck
• YouTubeyoutube.com/user/Merck
• Facebookfacebook.com/MerckInvents
• LinkedInlinkedin.com/company/merck
• Instagraminstagram.com/merck

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Capital Ventures